Cyproterone acetate in advanced male breast cancer.
Three male patients of 55, 63 and 71 years of age, with metastatic breast cancer, were treated with cyproterone acetate. Two patients showed complete remission, one lasting 21 months, another 51+ months and a third achieved partial remission lasting 9 months. These results suggest that cyproterone acetate may be useful in the treatment of advanced male breast cancer.
D000368:Aged; D000970:Antineoplastic Agents; D001943:Breast Neoplasms / Q000188:drug therapy*; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D000970:Antineoplastic Agents; D017373:Cyproterone Acetate; D003534:Cyproterone